Ascendis Pharma A/S Q1 2026 Financial Summary
Business Context and Reporting Period
This Form 6-K filing covers the unaudited condensed consolidated interim financial statements for the three months ended March 31, 2026. Ascendis Pharma A/S is a global biopharmaceutical company focused on its TransCon technology platform. Key business developments during the period include the U.S. FDA approval of YUVIWEL (navepegritide) for achondroplasia in February 2026 and the subsequent commercial launch in April 2026. The company also completed a mandatory exchange of American Depositary Shares (ADSs) for ordinary shares on Nasdaq in April 2026.
Key Financial Metrics
| Metric (EUR'000) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 246,601 | 100,954 |
| Gross Profit | 229,086 | 83,437 |
| Operating Profit | 24,812 | (104,212) |
| Net Profit | 629,339 | (94,626) |
| EPS (Basic) | 10.20 | (1.58) |
| Cash and Equivalents | 572,820 | 517,923 |
| Total Debt (Borrowings) | 896,664 | 871,786 |
Note: Total Debt includes Convertible Senior Notes (€448.2M), Royalty Funding Liabilities (€298.1M), and Lease Liabilities (€150.4M).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 144% to €246.6 million, driven primarily by YORVIPATH sales (€196.9M vs €44.7M in Q1 2025). SKYTROFA revenue declined slightly to €44.0M.
- Profitability Turnaround: The company reported an operating profit of €24.8 million, a reversal from an operating loss of €104.2 million in Q1 2025. This was driven by revenue growth and a €10.9 million reversal of prior inventory write-downs following YUVIWEL approval.
- Net Income Surge: Net profit reached €629.3 million, compared to a net loss of €94.6 million in the prior year. This is largely attributable to a non-cash income tax benefit of €677.5 million resulting from the recognition of previously unrecognized deferred tax assets in Denmark and the U.S.
- Expense Trends: R&D expenses decreased by €27.6 million to €59.0 million due to trial completions and inventory reversals. SG&A expenses increased by €44.2 million to €145.2 million due to commercial expansion.
Guidance, Outlook, and Risks
- Subsequent Events: On May 6, 2026, the company completed the optional redemption of its €575 million convertible notes via conversion into equity. Additionally, the company agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million, with income expected in Q2 2026.
- Strategic Shifts: In Q2 2026, the company announced the discontinuation of internal oncology development to pursue strategic alternatives for the asset.
- Liquidity: Management estimates existing cash and cash equivalents (€572.8 million) are sufficient to fund operations for at least 12 months. Operating cash flow was negative €7.7 million, primarily due to working capital movements (increased receivables) and the timing of revenue recognition.
- Risks: Key risks include ongoing litigation with BioMarin regarding patent infringement (though a key patent was revoked in Oct 2025), foreign currency exchange fluctuations, and the ability to sustain commercial growth for YORVIPATH and YUVIWEL.
Investor Verification Checklist
- Deferred Tax Assets: Verify the sustainability of the €679 million deferred tax asset recognition, which was the primary driver of net income.
- Convertible Note Redemption: Confirm the final settlement details and equity impact of the May 2026 conversion of the €575 million convertible notes.
- PRV Sale Closing: Monitor the closing of the $187.5 million Priority Review Voucher sale and the timing of revenue recognition.
- YUVIWEL Commercialization: Track early sales data for YUVIWEL following its April 2026 U.S. launch.
- Oncology Asset Strategy: Review updates on the strategic alternatives being pursued for the discontinued internal oncology program.